Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
- 1 August 2000
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 62 (3) , 245-252
- https://doi.org/10.1023/a:1006438507898
Abstract
Immunomodulatory strategies, such as antibody therapy and cancer vaccines, are increasingly being considered as potential adjuvant therapies in patients with advanced stage breast cancer to either...Keywords
This publication has 13 references indexed in Scilit:
- Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancerHuman Immunology, 1999
- Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cellsInternational Journal of Cancer, 1998
- A sensitive ELISPOT assay to detect low-frequency human T lymphocytesJournal of Immunological Methods, 1997
- High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.Journal of Clinical Oncology, 1997
- Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.The Journal of Experimental Medicine, 1995
- A Population-Based Serologic Survey of Immunity to Tetanus in the United StatesNew England Journal of Medicine, 1995
- Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.Proceedings of the National Academy of Sciences, 1995
- Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cellsInternational Journal of Cancer, 1992
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Assessment of delayed-type hypersensitivity in man: A comparison of the “Multitest” and conventional intradermal injection of six antigensClinical Immunology and Immunopathology, 1985